

China Pharmaceuticals Limited

**Company Registration Number:
2892748 (England and Wales)**

Report of the Directors and Unaudited Financial Statements

Period of accounts

Start date: 1st January 2012

End date: 31st December 2013

ACCOUNTS



China Pharmaceuticals Limited

Contents of the Financial Statements for the Period Ended 31st December 2013

	Page
Company Information	3
Directors' Report	4
Profit and Loss Account	5
Statement of total recognised gains and losses	6
Balance Sheet	7 to 8
Notes to the Financial Statements	9 to 10

China Pharmaceuticals Limited

Company Information for the Period Ended 31st December 2013

Director: M James

Company secretary: M. James

Registered office address: Coombe House
Bradford Peverell
DORCHESTER
Dorset
DT2 9SE

Company Registration Number: 2892748 (England and Wales)

China Pharmaceuticals Limited

Directors' Report for the Period Ended 31st December 2013

The director presents his report with the financial statements of the company for the period ended 31st December 2013

Principal activities

The principal activity of the company in the period under review was: supply of healthcare products to and within China, and consultancy related to the healthcare system and market in China.

The company has been endeavouring to re-establish connections with key employees of its former subsidiary operations in China, and rebuild a business.

Directors

The directors shown below have held office during the whole of the period from 1st January 2013 to 31st December 2013:

M. James

No directors were appointed to the company during the period

No directors resigned during the period

Political and charitable donations

No charitable donations were made during the year amounted.

No contributions were made to political organisations during the year.

Company policy on the employment of disabled persons

It is the company's policy to give employment to disabled persons wherever practicable. At present none of our full time staff is registered disabled.

The above report has been prepared in accordance with the provisions in part 15 of the Companies Act 2006.

This report was approved by the board of directors on 1st March 2014, and

Signed On Behalf Of The Board By:

Name: M. James Director



China Pharmaceuticals Limited

Profit and Loss Account For the period ended 31st December 2013

	Statutory accounts notes	2013	2012
Turnover:	1, 2	0	11,712
Cost of sales:		0	0
Gross profit or (loss):		0	0
Distribution cost:		0	0
Administrative expenses:	3 -5	6,568	0
Other operating income:		0	0
Operating profit or (loss):		(6,568)	(8,721)
Interest receivable and similar income:		0	0
Interest payable and similar charges:		0	0
Profit or (loss) on ordinary activities before taxation:		(6,568)	(8,721)
Tax on profit or (loss) on ordinary activities:	6		
Profit or (loss) for the financial year:		(6,568)	(8,721)

China Pharmaceuticals Limited

Statement of total recognised gains and losses for the period ended 31st December 2013

	£	£
Profit or (loss) for the period	(6,568)	(8,721)
Revaluation surplus or (deficit):	0	0
Total recognised gains or (losses) for the period:	(6,568)	(8,721)

China Pharmaceuticals Limited

Balance sheet as at 31st December 2013

		Statutory accounts notes <u>2013</u>	<u>2012</u>
A.	FIXED ASSETS		
	i. Intangible assets	0	0
	ii. Tangible assets	8 116,603	116,603
	iii. Investments	0	0
B.	CURRENT ASSETS		
	i. Stocks	9 31,613	31,613
	ii. Debtors	10 218,425	218,425
	iv. Investments	0	0
	v. Cash at bank and in hand	0	0
	TOTAL ASSETS	366,641	366,641
	LIABILITIES		
A.	Provision for liabilities and charges	0	0
B.	Creditors (more than one year)	12 0	0
C.	Accruals and deferred income	13 0	0
	TOTAL ASSETS LESS LIABILITIES	0	366,641
	CAPITAL AND RESERVES		
	i. Called up share capital	14 103,519	103,519
	ii. called up capital not paid	0	0
	iii. Share premium account	9,969,340	9,969,340
	iv. Revaluation reserve	0	0
	v. Other reserves	731,795	731,795
	vi. Profit and Loss account	16 (10,444,458)	(10,429,292)
	TOTAL CAPITAL AND RESERVES	360,073	(366,641)

For the year ending December 31st 2013 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts

The accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the Financial Reporting Standard for smaller Entities (effective 2008)

The financial statements were approved by the Board of Directors on 1st March 2014

SIGNED ON BEHALF OF THE BOARD BY:

Name: M. James  Director

The notes form part of these financial statements

China Pharmaceuticals Limited

Notes to the Financial Statements for the period ended 31st December 2013

1. Accounting policies

Basis of measurement and preparation of accounts

The financial statements have been prepared under the historic cost convention as modified by the revaluation of certain fixed assets and in accordance with the Financial Reporting Standard for Smaller Entities (Effective 2008)

Turnover policy

The turnover shown in the profit and loss account represents value recognised by the company in respect of goods and services supplied during the period, exclusive of Value Added Tax and trade discounts

Tangible fixed assets depreciation policy

Depreciation is provided, after taking into account any grants receivable, at the following annual rates in order to write off each asset over its estimated useful life. Freehold buildings -2% on cost or revalued amounts, Plant and Machinery -15% on cost, Fixtures and Fittings -10% on cost, Motor Vehicles -20% on cost

Intangible fixed assets amortisation policy

Intangible fixed assets (including purchased goodwill and patents) are amortised at rates calculated to write off the assets on a straight basis over their estimated useful economic lives, not to exceed twenty years. Impairment of intangible assets is only reviewed where circumstances indicate that the carrying value of an asset may not be fully recoverable.

Valuation information and policy

Stocks and work in progress are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items. Cost includes all direct expenditure and an appropriate proportion of fixed and variable overheads.

Other accounting policies

Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.. The interest element of these obligations is charged to the profit and loss account over the relevant period. The capital element of the future payments is treated as a liability.

Rentals paid under operating leases are charged to the profit and loss account on a straight line basis over the relevant period of the lease

Research and Development expenditure is written off in the year in which it is incurred.

Deferred taxation is provided in full in respect of taxation deferred by timing differences between the treatment of certain items for taxation and accounting purposes. Deferred taxation is calculated at the rates that are expected to apply in the periods when the timing differences will reverse and has not been discounted.

2. Turnover

All turnover took place in the UK

3. Operating profit or (loss)

Profit before tax is stated after taking into account consultancy income, and charging only travel and incidental office expenditures. Some progress has been made to estimate reliably the value of fixed and current assets held in the former subsidiary companies in China, which remain subject to further negotiation.

4. Director's remuneration

The sole director has taken zero remuneration in the period, and the company has not made any contributions towards a pension scheme

5. Employees

The company has had no employees during the period

6. Taxation

The company made a loss. No tax is due

7. Dividends

The company has paid no dividends in the period

8. Tangible assets

The company has no tangible assets in the UK. At the present time it has not been possible to ascertain whether in practice it may be possible to re-establish control over the assets formerly controlled in China, although it has been established that they have been properly repaired and maintained and are fully functional. The director does not believe that it is necessary or appropriate to change the value of the assets as shown in the accounts

9. Stocks

There are no stocks in the UK. Whether it will be possible to claim ownership over some or all of the stocks in China is uncertain, and is the subject of negotiation. The director's opinion is that there is no reason to change the figure shown in previously submitted accounts

10. Debtors

There are no debtors in the UK. Whether it will be possible to claim ownership over some or all of these debts is uncertain, and is the subject of negotiation. The director's opinion is that there is no reason to change the figure shown in previously submitted accounts

11. Creditors: amounts falling due within one year

There are no creditors entitled to be paid within one year

12. Creditors: amounts falling due after more than one year

There are no creditors due to be paid after more than one year.

13. Accruals and deferred income

There are no accruals or deferred income

14. Borrowings, leases and hire purchase agreements

The company has no borrowings, either in the UK or elsewhere, nor does it have any operating leases or hire purchase agreements

15. Called up share capital

The entire share capital of the company is in 5,263,161 called up Ordinary shares, all of which are fully paid up.

There has been no change during the period.

16. Profit and Loss Account.

	2013	2012
Retained Profit/(loss) from previous year	(10,444,458)	(10,429,292)
Income	0	11,712
Expenses	6,568	20,433
Profit or (Loss) for the period	(6,568)	(8,721)
Retained Loss at 31.12.2013	(10,451,026)	(10,444,458)

The Company became active in 2013, following a long period of dormancy, when the possibility arose for regaining some influence over, or cooperation with, its former subsidiary operations in China. Further negotiations have made little progress in resolving outstanding issues.

It has not been possible to generate any income in the UK this year. Expenses have been incurred in the process of reviving the business, and as a consequence, a further loss has been made.